Summary by Moomoo AI
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, completed a sale of 1,913 common shares on February 20, 2024. The transaction was executed at a price of $79.67 per share, resulting in a total market value of $152,408.71. Prior to this sale, Kasinger acquired 3,825 shares through the exercise of derivative securities on February 18, 2024. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics amount to 57,371 common shares. The sale represents an open market transaction, and the acquisition was a result of exercising options available to Kasinger.